Cybin Inc. Files 6-K with Clinical Program Update

Ticker: HELP · Form: 6-K · Filed: Apr 23, 2025 · CIK: 1833141

Sentiment: neutral

Topics: regulatory-filing, news-release, biotech

TL;DR

Cybin dropped a 6-K with a news release on April 23rd – likely clinical trial news.

AI Summary

On April 23, 2025, Cybin Inc. filed a Form 6-K, reporting a news release dated April 23, 2025. The news release, attached as Exhibit 99.1, likely contains important updates regarding the company's clinical programs. Doug Drysdale, CEO of Cybin Inc., signed the report.

Why It Matters

This filing indicates Cybin Inc. is providing material information to investors, likely related to its ongoing clinical trials in the psychedelic therapeutics space.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the underlying clinical trial information could carry significant risks and rewards typical of the biotech/pharma sector.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report a news release dated April 23, 2025, which is attached as Exhibit 99.1.

Who signed the Form 6-K on behalf of Cybin Inc.?

Doug Drysdale, Chief Executive Officer of Cybin Inc., signed the Form 6-K.

What is the filing date and period of report for this document?

The filing date and the conformed period of report for this document is April 23, 2025.

What is the SIC code for Cybin Inc.?

The Standard Industrial Classification (SIC) code for Cybin Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Which exhibit is attached to this Form 6-K filing?

Exhibit 99.1, a News Release dated April 23, 2025, is attached to this Form 6-K filing.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2025 by Doug Drysdale regarding CYBIN INC. (HELP).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing